OrbiMed Asia Leads $19M Series B Round In Biotech Start-Up InventisBio

For Digital Subscribers Only

Healthcare-focused investment firm OrbiMed Asia Partners has led a US$19 million series B round of financing in InventisBio, a biotech company dedicated to the discovery and development of novel medicines.

China Money Network

UNLOCK DATA
Subscribe & Access the Best Data and Intelligence on Chinese Venture Capital and Tech


Register Now

Want to read this important story?

Access thousands of news articles and data posts over the past 9 years!


Already have an account or paid subscription? Log in

China Expert network

RELATED NEWS



LEAVE A REPLY